What does “Crysvita patent CRIFF” mean?
“CRIFF” isn’t a standard, widely used public term tied to Crysvita (burosumab) patent status in the way you might see “expiry,” “exclusivity,” or “Bolar/entry” used in drug patent reporting. Without more context, “CRIFF” could be:
- a typo or shorthand from a specific country’s patent/medicines registry or legal filing,
- an internal code used by a database/vendor,
- a misspelling of another term (for example “cliff,” meaning a patent/exclusivity cliff where rights end close together).
If you can share where you saw “CRIFF” (country/regulator, database name, or the exact text around it), I can map it to the correct patent/exclusivity concept.
When do Crysvita patents or exclusivity typically “criff/cliff”?
Crysvita’s loss of market exclusivity is usually driven by a mix of:
- patent expiry for relevant claims (active ingredient, composition, methods),
- supplementary protection (where applicable),
- exclusivity periods that may delay generic/biosimilar entry even after some patents expire.
The exact “cliff” date depends on the jurisdiction (US vs EU vs UK vs other countries) and which specific patent family or exclusivity type the source is tracking. With only “Crysvita patent criff,” there isn’t enough detail to provide a reliable date.
Which countries have different “cliff” dates for Crysvita?
Patent and exclusivity timelines vary a lot by market. Users commonly look up:
- US patent expiry vs biosimilar entry timing (and any Hatch-Waxman/BPCIA-related effects),
- EU SPC (supplementary protection certificate) and patent expiry,
- UK transitional protections (if relevant),
- national reimbursement or regulatory exclusivity rules.
To answer precisely, I’d need the country/region you care about.
What should you check in a database when searching Crysvita “criff”?
If your goal is to find the date when competition can enter, the most useful fields to confirm are:
- the exact patent number or publication,
- whether the entry is tied to patent expiry or a separate exclusivity/SPC right,
- the jurisdiction,
- any listed litigation or “stay” effects.
Sharing the database screenshot/text would let me interpret the “CRIFF” label correctly.
What I need from you to give a concrete answer
Reply with one of these:
1) The jurisdiction (US, EU, UK, etc.), and where you saw “CRIFF” (site/database name), or
2) The full line you saw (even a partial sentence), or
3) Any patent number/publication associated with “Crysvita patent criff.”
Then I can tell you what the term means in that context and identify the relevant Crysvita patent/exclusivity “cliff” timing for that market.